Cargando…

Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is often managed with inhaled long-acting muscarinic antagonists (LAMAs), yet real-world data on healthcare resource utilization (HRU) by inhaler type are lacking. This study compared HRU after LAMA initiation with a soft mist inhaler (SMI) ve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singer, David, Bengtson, Lindsay G S, Elliott, Caitlin, Buikema, Ami R, Franchino-Elder, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732756/ https://www.ncbi.nlm.nih.gov/pubmed/33324047 http://dx.doi.org/10.2147/COPD.S284678

Ejemplares similares

Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium*
por: Colthorpe, Paul, et al.
Publicado: (2013)

Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices
por: Hira, Daiki, et al.
Publicado: (2018)

Reducing carbon footprint by switching to reusable soft-mist inhalers
por: Janson, Christer, et al.
Publicado: (2023)

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Investigating the Unbinding of Muscarinic Antagonists from the Muscarinic 3 Receptor
por: Buigues, Pedro J., et al.
Publicado: (2023)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

Muscarinic Receptor Agonists and Antagonists
por: Broadley, Kenneth J., et al.
Publicado: (2001)

Pharmacokinetic Study of Epinephrine Hydrofluoroalkane (Primatene MIST) Metered-Dose Inhaler
por: Kerwin, Edward M., et al.
Publicado: (2020)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease
por: Crater, Glenn D., et al.
Publicado: (2022)

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler
por: Hodder, Richard, et al.
Publicado: (2009)

Reduced Environmental Impact of the Reusable Respimat(®) Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers
por: Hänsel, Michaela, et al.
Publicado: (2019)

2726. Meningococcal Vaccination Among Patients Newly Diagnosed at High-Risk for Meningococcal Disease in the United States
por: Bengtson, Lindsay, et al.
Publicado: (2019)

Development and validation of a drug adherence index for COPD
por: Bengtson, Lindsay G S, et al.
Publicado: (2021)

Association between Medicare’s Hospital Readmission Reduction Program and readmission rates across hospitals by medicare bed share
por: Banerjee, Souvik, et al.
Publicado: (2021)

Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders
por: Dalby, Richard N, et al.
Publicado: (2011)

Multitargeting nature of muscarinic orthosteric agonists and antagonists
por: Myslivecek, Jaromir
Publicado: (2022)

Inhaler usability of a pressurized metered dose inhaler and a soft mist inhaler in patients with COPD: A simulated-use study
por: Ding, Bo, et al.
Publicado: (2018)

Night of the Mist
por: Colwell, Catherine
Publicado: (1960)

Hospital readmission performance and patterns of readmission: retrospective cohort study of Medicare admissions
por: Dharmarajan, Kumar, et al.
Publicado: (2013)

The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT(3) receptors
por: Lochner, Martin, et al.
Publicado: (2016)

Novel long‐acting antagonists of muscarinic ACh receptors
por: Randáková, Alena, et al.
Publicado: (2018)

Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma
por: Aalbers, René, et al.
Publicado: (2017)

Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers
por: W. H. Kocks, Janwillem, et al.
Publicado: (2022)

Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered‐Dose Inhaler
por: MacGregor, TR, et al.
Publicado: (2016)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

Readmission After Pancreatectomy for Pancreatic Cancer in Medicare Patients
por: Reddy, Deepthi M., et al.
Publicado: (2009)

Clinical and sociodemographic risk factors for readmission of Medicare beneficiaries
por: Holloway, James J., et al.
Publicado: (1988)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Wing Patterns in the Mist
por: Martin, Arnaud, et al.
Publicado: (2010)

The CERN version of MIST
por: McCarroll, S J
Publicado: (1963)

The Cholera Mist Again
Publicado: (1866)

Dust, Mist and Clouds
Publicado: (1883)

Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy
por: Palli, Swetha R., et al.
Publicado: (2020)

Association Between Financial Incentives in Medicare's Hospital Readmissions Reduction Program and Hospital Readmission Performance
por: Hoffman, Geoffrey J., et al.
Publicado: (2020)

Muscarinic Receptors and Their Antagonists in COPD: Anti-Inflammatory and Antiremodeling Effects
por: Karakiulakis, George, et al.
Publicado: (2012)

Long-acting muscarinic antagonists vs. long-acting β (2) agonists in COPD exacerbations: a systematic review and meta-analysis
por: Maia, Israel Silva, et al.
Publicado: (2017)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016)

Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis
por: Navaie, Maryam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fahkspg0tf8m2pa8elhtbq7078